Rainbow Childrens Medicare growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+12.4%+16.9%+10.5%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+11.1%+14.2%+8.2%
+12.0%+10.9%+3.5%
+15.3%+11.9%+2.8%
+14.4%+12.1%+2.3%
+16.7%+9.5%+22.2%
+12.8%+16.6%+18.8%
+6.1%+23.1%−1.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

RAINBOW₹1,196.80

Rainbow Childrens Medicare Ltd.

· Pharma & Health
₹ CrorePeersAPOLLOHOSPFORTISKIMSPOLYMEDPFIZERONESOURCEJUBLPHARMAVIJAYAMcap ₹12,155 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+10.5+16.9+12.4—
EBITDA Growth—+8.2+14.2+11.1—
EBIT Growth—+3.5+10.9+12.0—
Net Income Growth—+2.8+11.9+15.3—
EPS Growth—+2.3+12.1+14.4—
Total Assets Growth—+22.2+9.5+16.7—
Total Equity Growth—+18.8+16.6+12.8—
Cash from Operations Growth—-1.8+23.1+6.1—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.